and thank for joining. you, everyone, you, Thank
the and clinical of a with program, recent development accomplishments I review begin upcoming will call milestones. our
a We up we will results, for will open Q&A. then financial with the review it follow of and then
new as Aspire our Starting Australia as with is into gemcitabine evaluating trial patient and metastatic the our name the our Ivospemin pancreatic first enrolled. nab-paclitaxel for of which untreated Phase III or adenocarcinoma expansion program, announced in for August, well international ductal with without SBP-XXX we generic
Italy. sites approval of regulatory opening announced trial also in Spain, We the France and for
treatment initiation South continuing on Australia United to disease options. States, XX effective order deliver for approximately throughout site sites in we pancreatic cancer, are deadly With with treatment enrollment ultimately a more and few to Korea, a focus Europe, planned and the
early to significant by full of mid-XXXX. opened by a year-end global sites number complement that sites expect the with opened We of will be
trial will patients, and the The endpoint XXX sample primary survival. overall be is size
as use of well. study complete will We well still merits utilization. analysis take to anticipated allows enrollment interim the XX the interim available as for interim to in The is approximately It assess to the continuing us analysis with as ensure optimal the overall survival early XXXX. analysis for months resource
excited are move a as these in interim towards little expected from have We over now. year X to recent we approvals analysis forward the
Turning our to funded to the or polyposis familial adenomatous is anticipated One-Two trial FAP, mid-XXXX licensing with by is and registration partner, Flynpovi Therapeutics. begin
ensure the all to with the key We trial on of are One-Two closely the FDA working aspects alignment before with trial commences.
trial the we Canada, for authorities regarding European rights approval Europe. the will advice and we the the As utilize seek U.S. registration outside from sites the will and in of of the trial European clinical utilization retain
reminder, Phase Eflornithine GI risk and a As Flynpovi for Sulindac or or alone, a gastrointestinal a versus and evaluating III either a agent surgery XXX% reduction study the prior lower in group. need showed
to be the currently data intended therapies and the trial. the there group GI focus the this As lower of treatment exciting registration is for of approved new are no drug is FAP,
to look by NCI, Cancer Group, SWOG, or in also known and is funded Institute, cancer. to in is One-Two Southwest analysis half National primary Sulindac, and and we Phase prevent adenomas we PACES trial patients futility ongoing X recurrence the combination forward high-risk also Lastly, colon partnership with of the X collaboration and the known of cancers XXXX. or Flynpovi, in double-blind, have second the Eflornithine III stage Oncology with the trial first a with in of This placebo-controlled as an as colorectal trial of rectal
II Phase studies. to Moving
NCI. Children's Oncology relapsed/refractory trial is and First, the funded in sachets. eflornithine or utilizing trial is the neuroblastoma there an through This COG, ongoing Group,
Juvenile be also This in Indiana onset Foundation study a and will is supported Type Eflornithine the JDRF. II utilizing by Research XXXX, starting University tablets. in trial X Phase Diabetes early diabetes early or We
In Phase we I development, we starting. will programs X have that be
as will preclinical pathways KEYTRUDA Eflornithine of models, cells. by evaluating non-small by in cytotoxic lung cell and Eflornithine in be mutation year-end, that in cancer. of non-small combination increasing suggest population to cancer poorly a as STKXX tumor-specific increased efficacy CDX-positive metabolic with role polyamine to resistance sachets the in on First, cell mutant play PD-X tumor-associated improves populations analyses tumor anti-PD-X may the treatment immunotherapy. STKXX we well bioinformatic checkpoint T respond inhibitors T expression opening In cell lung alterations
trial rates. it portion the combining look a as proof-of-concept to trial on is relationship other possibility for If and is opens tumors as The combining possibility of with be inhibitor checkpoint positive, such the between system. response will other the it Phase immune fully with starting well as we the funded, CAR the therapy in improve and T trial polyamines focused immunotherapies, this I as clinical forward to this first
Our begin Ivospemin the second population. of focus in I which Phase is to evaluation the XXXX platinum-resistant half the first scheduled will on of program, cancer in ovarian
John reminder, School to of a identify with Hopkins As Medicine this University collaborated indication. we've
Ivospemin later tumor immune Additionally, a was significantly and International decrease mature Journal mice Cancer Analogue and the burden. cancer of of in SBP-XXX survival Polyamine Molecular the Therapeutic. of Polyamine the titled on published overall The was in data a of a Metabolism injected presented and Expanded Modulator with Potential poster as VDIDX-positive prolonged Sciences, treatment competent with ovarian showed
strong in median with data supports cancer that in determined studies an cell publication ovarian mouse cancer across a range The survival initiate model. in clinical program. to ovarian XX% exceptionally The in highlighted viability, SBP-XXX an reduced viability ovarian that increase resulting cellular VDIDX-positive vitro the adenocarcinoma efforts a cancer reduction in types broad of
work investigator-initiated to neoadjuvant begin necessary Lastly, we completed pancreatic a have preclinical trial. cancer
key necessary XXXX. with early protocol the institutional finalize are approvals obtain trial to opinion working this open We leaders by and to the the
milestones. to Turning
our in untreated patients early the trials by various cancer anticipate final pancreatic of in XXXX. execution Phase our data we trial continued program, and X early to addition diabetes onset I development year-end metastic onset Type In from or announcing
year-end gastric well as completed of prevention previously or analysis from trial the as by data final for PACES XXXX. cancer half first XXXX be will the the futility early in trial There
We the also the lung in trial I STKXX non-small Phase anticipate the mid-XXXX combination ASPIRE from from Eflornithine-KEYTRUDA XXXX. trial cell the the analysis in by cancer data and interim early
In progress summary, have tremendous year-to-date. made QX we in and
against value move excited are to and into enhance ahead we We executing milestones. by stockholder onwards QX our as
stop Sue financials. review will over here it turn I to and to the
